Wired News – Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration

Stock Monitor: Spring Bank Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPHT as the Company’s latest news hit the wire. On May 01, 2018, the New York-based biopharmaceutical Company announced that it has completed patient enrollment in its Phase-2a clinical trial of Zimura® (avacincaptad pegol) in patients with wet age-related macular degeneration (AMD). Zimura is administered in combination with Lucentis® (ranibizumab), an anti-vascular endothelial growth factor (anti-VEGF) agent, in treatment naïve patients with wet AMD. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), which also belongs to the Healthcare sector as the Company Ophthotech. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SBPH

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Ophthotech most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=OPHT

Ophthotech to Report Initial Top-line Data from Phase-2a Study Before End of 2018

A total of 64 patients have been enrolled into this Phase-2a dose-ranging, open-label, multi-center trial. This uncontrolled trial is designed to assess safety at different dosages and to detect a potential efficacy signal. Ophthotech will evaluate data at month 6 and expects initial top-line data to become available before the end of 2018.

Clinical Data will be Analyzed to Assess Whether to Proceed to a Controlled Trial of Zimura® Combination Therapy in Wet AMD

Kourous Rezaei, M.D., Chief Medical Officer of Ophthotech, stated that the Company is pleased with the enthusiasm shown by the principal investigators in the recruitment for this clinical trial leading to on time enrollment of patients.

Kourous added that following the completion of this trial, clinical data will be analyzed to assess whether to proceed to a randomized, sham controlled clinical trial of Zimura® combination therapy in wet AMD.

Zimura® is Being Evaluated in Clinical Trials in Patients with Geographic Atrophy Secondary, Dry AMD, STGD1, and IPCV

Zimura® is also currently being investigated as monotherapy in a Phase-2b clinical trial for patients with geographic atrophy secondary to dry AMD. On January 16, 2018, the Company enrolled first patient in the Phase-2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® in patients with autosomal recessive Stargardt disease (STGD1). STGD1 is an inherited orphan retinal disease-causing vision loss during childhood or adolescence. Further, Zimura® is being evaluated as combination therapy with Eylea® (aflibercept), an anti-VEGF agent, in patients with idiopathic polypoidal choroidal vasculopathy (IPCV).

About Wet Age-Related Macular Degeneration

AMD is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. In wet AMD, In the wet AMD, pathologic choroidal neovascular membranes (CNVM) develop under the retina. The CNVM can leak fluid and blood and, if left untreated, ultimately cause a centrally blinding disciform scar.

About Zimura®

Zimura® is designed to target and inhibit the complement protein C5, a central component of the complement cascade. Inhibition of C5 in the complement cascade prevents the formation of key terminal fragments (C5a and C5b-9) regardless of which of the three complement pathways (classical, lectin or alternative) induced their generation. C5b-9 is involved in the formation of the membrane attack complex (MAC: C5b-9), which can cause cell death through disruption of the cell membrane. Furthermore, when used in combination with anti-VEGF therapy, Zimura® may counteract the anti-VEGF induced complement upregulation, thereby providing the rationale as a potential combination therapy for patients with wet AMD and IPCV.

About Ophthotech Corp.

Founded in 2007, Ophthotech is a science-driven biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The Company’s multi-track strategy is to leverage its clinical experience and retina expertise to develop therapies for large market, age-related retinal diseases, and for orphan eye diseases with a focus on underserved patients.

Stock Performance Snapshot

May 02, 2018 – At Wednesday’s closing bell, Ophthotech’s stock advanced 1.53%, ending the trading session at $2.66.

Volume traded for the day: 102.30 thousand shares.

Stock performance in the previous six-month period – up 12.71%

After yesterday’s close, Ophthotech’s market cap was at $95.87 million.

Price to Earnings (P/E) ratio was at 0.57.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 498366